Home › All Companies › VERA

Vera Therapeutics, Inc. (VERA)

AI-Powered SEC Filing Analysis

Insider Trading Filed: 2026-04-15

Key Insights

  • The filing indicates that the CEO, Marshall Fordyce, has sold a significant amount of Vera Therapeutics' Class A common stock, totaling over 22,000 shares. This may raise concerns about management's confidence in the company's near-term prospects.
  • The shares were sold pursuant to a 10b5-1 trading plan, suggesting the transactions were pre-planned and not necessarily driven by new information. However, the timing and magnitude of the sales could still be viewed negatively by investors.
  • The CEO still holds a substantial number of shares, both directly and indirectly through a trust and a GRAT, indicating he maintains a significant ownership stake in the company. This may help mitigate concerns about the insider selling.
Sentiment: Negative Significance: 6/10
View Original Filing →
Insider Trading Filed: 2026-03-25

Key Insights

  • Jane Wright-Mitchell, the Chief Legal Officer of Vera Therapeutics, Inc. (VERA), acquired 42,403 shares of Class A Common Stock through restricted stock units (RSUs), indicating her commitment to the company.
  • Wright-Mitchell also received a stock option to purchase 56,850 shares of Class A Common Stock, further aligning her interests with those of the company and its shareholders.
  • The vesting schedules for both the RSUs and the stock option suggest a long-term focus, with the RSUs vesting over 4 years and the stock option vesting over 9 years, indicating Wright-Mitchell's belief in the company's long-term potential.
Sentiment: Positive Significance: 6/10
View Original Filing →

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.